|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 30, 2017 ) HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
Publisher's analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-hospital-acquired-pneumonia-hap-drugs-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001795470/sample .
Other prominent vendors
- Arsanis
- AstraZeneca
- Combioxin
- Mylan
- Shinogi
- Sun Pharmaceutical Industries
- Teva Pharmaceutical
- The Medicines Company
- Theravance Biopharma
Market driver
- Unmet demand due to lack of available treatment for MDR microorganisms
- For a full, detailed list, view our report
Market challenge
- Growing cases of MDR microorganisms
- For a full, detailed list, view our report
Market trend
- Combination therapy for the treatment of HAP
- For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001795470/buying .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
